N-methyl-1-[2-sulfo-4-(trioxidanylsulfanyl)phenyl]methanimine oxide

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-methyl-1-[2-sulfo-4-(trioxidanylsulfanyl)phenyl]methanimine oxide
• 化学式: C8H9NO7S2
• 分子量: 295.3
• InChiKey: RFIVQWPORJNLEW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.5
• 重原子数：
  18
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  156
• 氢给体数：
  2
• 氢受体数：
  8

文献信息

• Methods for treating brain injury
  申请人：HOUGH EAR INSTITUTE

  公开号：US10022346B2

  公开（公告）日：2018-07-17

  The treatment options for treating blast-induced and noise-induced traumatic brain injury and tinnitus are limited. Thus, the current invention provides methods for treating traumatic brain injury and tinnitus. The methods involve administering a pharmaceutically effective amount of a composition comprising 2,4-disulfonyl α-phenyl tertiary butyl nitrone and N-acetylcysteine (NAC).

  治疗爆炸和噪音引起的创伤性脑损伤和耳鸣的方法十分有限。因此，本发明提供了治疗脑外伤和耳鸣的方法。这些方法包括给药有效量的组合物，该组合物包含 2,4-二磺酰基 α-苯基叔丁基硝酮和 N-乙酰半胱氨酸（NAC）。
• METHODS FOR TREATING BRAIN INJURY
  申请人：Kpoke Richard D.

  公开号：US20140187631A1

  公开（公告）日：2014-07-03

  The treatment options for treating blast-induced and noise-induced traumatic brain injury and tinnitus are limited. Thus, the current invention provides methods for treating traumatic brain injury and tinnitus. The methods involve administering a pharmaceutically effective amount of a composition comprises 2,4-disulfonyl α-phenyl tertiary butyl nitrone and N-acetylcysteine (NAC).
• METHODS FOR ENHANCING SYNAPTOGENESIS AND NEURITOGENESIS
  申请人：HOUGH EAR INSTITUTE

  公开号：US20180117115A1

  公开（公告）日：2018-05-03

  Disclosed here is a method for enhancing synaptogenesis and/or neuritogenesis, reducing neurodegeneration, and/or reducing accumulation or aggregation of Tau proteins in a subject suffering from cochlear synaptopathy or vestibular synaptopathy or a central nervous system disease or condition, comprising administering to said subject in need thereof an effective amount of 2,4-disulfonyl α-phenyl tertiary butyl nitrone (2,4-DSPBN) or a pharmaceutically acceptable salt thereof. The method may further comprise administrating N-acetylcysteine (NAC) to the subject.
• FORMULATIONS OF N-ACETYLCYSTEINE AND USES THEREOF
  申请人：Otologic Pharmaceutics, Inc.

  公开号：US20180200192A1

  公开（公告）日：2018-07-19

  Disclosed herein are compositions comprising a first compound that is N-acetylcysteine or a salt thereof, optionally a second compound that is a pharmaceutically acceptable compound capable of forming a radical adduct; and a coating layer encapsulating at least the first compound. Also disclosed are methods of use and manufacture.
• US9289404B2
  申请人：——

  公开号：US9289404B2

  公开（公告）日：2016-03-22